vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $1.7M, roughly 178.9× Arcellx, Inc.). Bio-Techne runs the higher net margin — 12.8% vs -3513.4%, a 3526.3% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -89.2%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -79.5%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ACLX vs TECH — Head-to-Head
Income Statement — Q4 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $1.7M | $295.9M |
| Net Profit | $-58.1M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3850.2% | 18.4% |
| Net Margin | -3513.4% | 12.8% |
| Revenue YoY | -89.2% | -6.4% |
| Net Profit YoY | -23.4% | 68.3% |
| EPS (diluted) | $-1.01 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7M | $295.9M | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $7.6M | $317.0M | ||
| Q1 25 | $8.1M | $316.2M | ||
| Q4 24 | $15.3M | $297.0M | ||
| Q3 24 | $26.0M | $289.5M | ||
| Q2 24 | $27.4M | $306.1M | ||
| Q1 24 | $39.3M | $303.4M |
| Q4 25 | $-58.1M | $38.0M | ||
| Q3 25 | $-55.8M | — | ||
| Q2 25 | $-52.8M | $-17.7M | ||
| Q1 25 | $-62.3M | $22.6M | ||
| Q4 24 | $-47.1M | $34.9M | ||
| Q3 24 | $-25.9M | $33.6M | ||
| Q2 24 | $-27.2M | $40.6M | ||
| Q1 24 | $-7.2M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -3850.2% | 18.4% | ||
| Q3 25 | -1248.3% | — | ||
| Q2 25 | -777.4% | -7.5% | ||
| Q1 25 | -847.6% | 12.2% | ||
| Q4 24 | -348.2% | 16.0% | ||
| Q3 24 | -129.1% | 13.8% | ||
| Q2 24 | -127.8% | 15.0% | ||
| Q1 24 | -40.3% | 22.1% |
| Q4 25 | -3513.4% | 12.8% | ||
| Q3 25 | -1127.1% | — | ||
| Q2 25 | -698.6% | -5.6% | ||
| Q1 25 | -766.0% | 7.1% | ||
| Q4 24 | -308.4% | 11.7% | ||
| Q3 24 | -99.4% | 11.6% | ||
| Q2 24 | -99.3% | 13.3% | ||
| Q1 24 | -18.3% | 16.2% |
| Q4 25 | $-1.01 | $0.24 | ||
| Q3 25 | $-0.99 | — | ||
| Q2 25 | $-0.94 | $-0.11 | ||
| Q1 25 | $-1.13 | $0.14 | ||
| Q4 24 | $-0.87 | $0.22 | ||
| Q3 24 | $-0.48 | $0.21 | ||
| Q2 24 | $-0.51 | $0.26 | ||
| Q1 24 | $-0.14 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $450.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $402.4M | $2.0B |
| Total Assets | $604.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $450.3M | $172.9M | ||
| Q3 25 | $461.4M | — | ||
| Q2 25 | $453.1M | $162.2M | ||
| Q1 25 | $543.3M | $140.7M | ||
| Q4 24 | $587.4M | $177.5M | ||
| Q3 24 | $574.3M | $187.5M | ||
| Q2 24 | $516.7M | $152.9M | ||
| Q1 24 | $573.9M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $402.4M | $2.0B | ||
| Q3 25 | $440.8M | — | ||
| Q2 25 | $392.2M | $1.9B | ||
| Q1 25 | $416.9M | $2.0B | ||
| Q4 24 | $454.8M | $2.1B | ||
| Q3 24 | $483.0M | $2.1B | ||
| Q2 24 | $487.2M | $2.1B | ||
| Q1 24 | $496.6M | $2.0B |
| Q4 25 | $604.0M | $2.5B | ||
| Q3 25 | $655.9M | — | ||
| Q2 25 | $619.1M | $2.6B | ||
| Q1 25 | $648.1M | $2.6B | ||
| Q4 24 | $711.3M | $2.7B | ||
| Q3 24 | $764.9M | $2.7B | ||
| Q2 24 | $734.3M | $2.7B | ||
| Q1 24 | $779.7M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-58.2M | — |
| Free Cash FlowOCF − Capex | $-58.9M | — |
| FCF MarginFCF / Revenue | -3563.4% | — |
| Capex IntensityCapex / Revenue | 46.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-58.2M | — | ||
| Q3 25 | $-49.2M | — | ||
| Q2 25 | $-39.7M | $98.2M | ||
| Q1 25 | $-63.1M | $41.1M | ||
| Q4 24 | $-46.0M | $84.3M | ||
| Q3 24 | $30.7M | $63.9M | ||
| Q2 24 | $-36.2M | $75.5M | ||
| Q1 24 | $-31.9M | $81.0M |
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | $93.3M | ||
| Q1 25 | $-63.9M | $31.0M | ||
| Q4 24 | $-47.5M | $77.5M | ||
| Q3 24 | $28.4M | $54.7M | ||
| Q2 24 | $-39.5M | $57.5M | ||
| Q1 24 | $-38.3M | $64.5M |
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | 29.4% | ||
| Q1 25 | -786.4% | 9.8% | ||
| Q4 24 | -311.3% | 26.1% | ||
| Q3 24 | 109.2% | 18.9% | ||
| Q2 24 | -144.1% | 18.8% | ||
| Q1 24 | -97.7% | 21.3% |
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | 1.5% | ||
| Q1 25 | 9.6% | 3.2% | ||
| Q4 24 | 9.8% | 2.3% | ||
| Q3 24 | 8.8% | 3.2% | ||
| Q2 24 | 11.7% | 5.9% | ||
| Q1 24 | 16.4% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
